Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be at least 18 years of age;~* Provide written informed consent~* Have a reported or documented history of dry eye for at least 6 months prior to Visit 1~* Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1~* Report a score of ≥ 2 on a Ocular Discomfort \& 4-symptom questionnaire in at least one symptom at Visits 1 and 2~* Have a Schirmer's Test score of ≤10mm and ≥1mm in at least one eye at Visits 1and 2~* Have a pre-CAE conjunctival redness score ≥ 1 according to the Conjunctival Redness for Dry Eye Scale in at least one eye at Visits 1 and 2~* Have a corneal fluorescein staining score of ≥ 2 in at least one region (e.g. inferior, superior, or central) at Visits 1 and 2~* Have a sum corneal fluorescein staining score of ≥ 4, based on the sum of the inferior, superior, and central regions at Visits 1 and 2~* Have a total lissamine green conjunctival score of ≥ 2, based on the sum of the temporal and nasal regions at Visits 1 and 2~* Demonstrate a response to the CAE at Visits 1 and 2 as defined by:~  1. Having at least a ≥1 point increase in fluorescein staining in the inferior region in at least one eye following CAE exposure~ 2. Reporting an Ocular Discomfort Score ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure (if a subject has an ocular discomfort rating of 3 at time = 0 for an eye, s/he must report an ocular discomfort rating of 4 for two consecutive measurements for that eye) Note: a subject cannot have an ocular discomfort score of 4 at time = 0)~Exclusion Criteria:~* Have any clinically significant slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction, ocular rosacea, lid margin inflammation or active ocular allergies that require therapeutic treatment~* Have any clinically significant (CS) posterior chamber findings, or a history of such findings/disorders, that may include exudative (i.e., wet) age-related macular degeneration, retinal vein occlusion, diabetic retinopathy, glaucoma, ocular hypertension, or any other retinal or optic nerve disease/disorder that require therapeutic treatment and/or in the opinion of the Investigator may interfere with study parameters~* Have worn contact lenses within 48 hours prior to Visit 1 or anticipate using contact lenses during the study~* Have laser-assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery and/or any other ocular surgical procedure within 12 months prior to Visit 1; or have any ocular surgical procedure scheduled to be conducted during the study period~* Have had any surgeries of the ocular surface or lid in the past 6 months~* Have a history of lacrimal duct obstruction in either eye within 12 months prior to Visit 1~* Have used temporary (i.e., collagen) punctal plugs within 12 weeks prior to Visit 1 or anticipate their use during the study period~* Have permanent punctal plugs inserted or removed - including falling out - or have had surgical punctal occlusion within 12 weeks prior to Visit 1 or anticipate any such event at any time during the study period~* Use any of the following treatments in the period indicated before Visit 1 or anticipate their use at any time during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IC265 Ophthalmic Solution 1% (Type: EXPERIMENTAL): 1 drop will be instilled in each eye twice daily.
- Placebo Ophthalmic Solution (Vehicle) (Type: PLACEBO_COMPARATOR): 1 drop will be instilled in each eye twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).